

B1
1. (Amended) A pharmaceutical composition, comprising a diaminoalkyl compound and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition attenuates the effect of pathogenic bacterial enterotoxins.

B2
4. (Amended) The composition of claim 1, wherein the gastrointestinal disorders result from an infection by an organism selected from the group consisting of *Shigella* spp. enteropathogenic *E. coli*, enterohemorrhagic *E. coli*, enterotoxigenic *E. coli*, enteroaggregative *E. coli*, uropathogenic *E. coli*, meningitis-causing *E. coli* K-1, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia enterocolitica*, *Mycobacterium bovis*, *Listeria monocytogenes*, *Vibrio cholerae*, *Streptococcus pyogenes*, *Campylobacter jejuni*, and *Bacteroides fragilis*.

B3
7. (Amended) The method of claim 10, wherein the host is a human.

8. (Amended) The method of claim 10, wherein the pathogenic bacterial enterotoxins are produced by a *Shigella* spp.

Rule 1120 42-2
B4
(New) The pharmaceutical composition of claim 1, wherein the pharmaceutical composition also attenuates transepithelial migration of polymorphonuclear leukocytes.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

43

~~10~~

(New) A method of attenuating the effect of pathogenic bacterial enterotoxins, comprising obtaining a pharmaceutical composition comprising a diaminoalkyl compound and a pharmaceutical carrier, and administering to a host an amount of the pharmaceutical composition effective to attenuate the effect of pathogenic bacterial enterotoxins.

44

~~11~~

43

(New) The method of claim 10, wherein the pathogenic bacterial enterotoxins are produced by one or more of *Shigella* spp., enteropathogenic *E. coli*, enterohemorrhagic *E. coli*, enterotoxigenic *E. coli*, enteroaggregative *E. coli*, uropathogenic *E. coli*, meningitis-causing *E. coli* K-1, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia enterocolitica*, *Mycobacterium bovis*, *Listeria monocytogenes*, *Vibrio cholerae*, *Streptococcus pyogenes*, *Campylobacter jejuni*, or *Bacteroides fragilis*.

45

~~12~~

43

(New) The method of claim 10, wherein the diaminoalkyl compound is cadaverine. ✓

46

~~13~~

43

(New) The method of claim 10, wherein the diaminoalkyl compound is putrescine. ✓

47

~~14~~

43

(New) The method of claim 10, wherein the pharmaceutical composition is also in an amount effective to attenuate transepithelial migration of polymorphonuclear leukocytes.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com